Poster Spotlight 4: Risk, Genetics, and Outcome

Moderator

Fergus J. Couch, Mayo Clinic, Rochester, MN

Presentation numberPD4-01

Preservative Food Additives and Breast Cancer Incidence in the NutriNet-Santé Cohort

Laurent Zelek, Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, CRESS, EREN, Paris, France

Presentation numberPD4-02

An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease

Celine M Vachon, Mayo Clinic, Rochester, MN

Presentation numberPD4-03

Physical Activity, Reproductive Factors, and Breast Cancer Risk: A Prospective Cohort Study using data from the UK Biobank

Hannah Harsanyi, Alberta Health Services, Calgary, AB, Canada

Presentation numberPD4-04

Impact of Polygenic Risk Scores on Breast Cancer Risk Assessment and Clinical Decision Making in Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2: Results from the Prospective Multisite GENRE-2 Clinical Trial

Siddhartha Yadav, Mayo Clinic, Rochester, MN

Presentation numberPD4-05

Partially functional (hypomorphic) missense variants in BRCA2 are reduced penetrance pathogenic variants

Huaizhi Huang, Mayo Clinic, Rochester, MN

Presentation numberPD4-06

Discussant: Genetic and Environmental Risk Factors

Tuya Pal, Vanderbilt University Medical Center, Nashville, TN

Presentation numberPD4-07

Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study

Matteo Lambertini, University of Genova, Genoa, Italy

Presentation numberPD4-08

Real-world biomarker testing patterns in US patients with HER2-negative metastatic breast cancer

Siddhartha Yadav, Mayo Clinic, Rochester, MN

Presentation numberPD4-09

Impact of Duration of Adjuvant Endocrine Therapy on Clinical Outcomes in BRCA pathogenic variant Carriers with HR+/HER2- Early Breast Cancer

Paola Zagami, European Institute of Oncology (IEO), university of Milan, Milan, Italy

Presentation numberPD4-10

The prognosis of invasive early hormone receptor positive HER2 negative breast cancer in women harboring a pathogenic or likely pathogenic TP53 germline variant.

Renata Sandoval, Hospital Sírio Libanes, Sao Paulo, Brazil

Presentation numberPD4-11

Contralateral Breast Cancer Risk in Women with PALB2-Associated Breast Cancer

Kelly Metcalfe, Women's College Research Institute, Toronto, ON, Canada

Presentation numberPD4-12

Discussant: Genetics and Outcomes

Banu Arun, MD Anderson Cancer Center, Houston, TX